Pentagastrin testing in patients with renal insufficiency: Normal responsivity of mature calcitonin

被引:18
作者
Lissak, B
Baudin, E
Cohen, R
Barbot, N
Meyrier, A
Niccoli, P
Bouyge, N
Modigliani, E
机构
[1] Hop Avicenne, Serv Endocrinol, F-93009 Bobigny, France
[2] CHU Angers, Serv Endocrinol, Angers, France
[3] Hop Avicenne, Serv Nephrol, F-93009 Bobigny, France
[4] Hop Enfants La Timone, Serv Endocrinol & Malad Metab, Marseille, France
[5] Hop St Antoine, Serv Cent Med Nucl, Lab Immunoanal, F-75571 Paris, France
关键词
D O I
10.1089/thy.1998.8.265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Calcitonin (CT) is the most sensitive tumor marker for medullary thyroid carcinoma available, but it lacks specificity. Chronic renal failure (CRF) is known to be associated with elevations of serum immunoreactive calcitonin. Using an immunoradiometric assay to detect only mature CT, we evaluated the basal CT level and its response to pentagastrin in 30 patients with CRF and compared these data with those obtained in 71 controls. Basal mature CT was significantly higher (p < 0.05) in patients with CRF (3.55 pg/mL) than in controls (2.00). Among these patients, 20% had basal CT levels more than 10 pg/mL with a maximum of 51 pg/mL. Peak CT values (highest value obtained 3 or 5 minutes after pentagastrin) were comparable in the two groups. Among patients with CRF, 10% had peak CT values greater than 30 pg/mL with a maximum of 53 pg/mL, In this group of patients, no correlation was found between CT (at any time during the test) and parathyroid hormone, calcium, phosphate, or creatinine clearance. Men had significantly higher CT values compared with women at each time point tested, including peak values, Patients with CRF, who have not yet undergone dialysis, have moderately elevated basal CT levels, but have normal pentagastrin-stimulated peak CT levels.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 21 条
[1]   C-CELL HYPERPLASIA IN THYROID-TISSUE ADJACENT TO FOLLICULAR CELL TUMORS [J].
ALBORESSAAVEDRA, J ;
MONFORTE, H ;
NADJI, M ;
MORALES, AR .
HUMAN PATHOLOGY, 1988, 19 (07) :795-799
[2]   PENTAGASTRIN STIMULATION TEST AND EARLY DIAGNOSIS OF MEDULLARY-THYROID CARCINOMA USING AN IMMUNORADIOMETRIC ASSAY OF CALCITONIN - COMPARISON WITH GENETIC SCREENING IN HEREDITARY MEDULLARY-THYROID CARCINOMA [J].
BARBOT, N ;
CALMETTES, C ;
SCHUFFENECKER, I ;
SAINTANDRE, JP ;
FRANC, B ;
ROHMER, V ;
JALLET, P ;
BIGORGNE, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01) :114-120
[3]  
BARBOT N, 1991, ANN ENDOCRINOL-PARIS, V52, P109
[4]  
BARBOT N, 1997, ANN ENDOCRINOL, V58, P302
[5]  
Becker KL, 1996, PRINCIPLES PRACTICE, P474
[6]   EARLY DIAGNOSIS OF THE MULTIPLE ENDOCRINE NEOPLASIA TYPE-2 SYNDROME - CONSENSUS STATEMENT [J].
CALMETTES, C ;
PONDER, BAJ ;
FISCHER, JA ;
RAUE, F ;
BODY, JJ ;
BRANDI, M ;
GARCIAAMEIJEIRAS, A ;
HANSEN, HS ;
KOUTRAS, DA ;
LENOIR, GM ;
LIMBERT, E ;
MOLLER, P ;
TELENIUSBERG, M ;
VASEN, HFA .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (11) :755-760
[7]   SERUM GASTRIN AND SERUM CALCITONIN IN PATIENTS WITH CHRONIC RENAL-FAILURE [J].
CHRISTENSEN, CK ;
NIELSEN, HE ;
KAMSTRUP, O ;
OLSEN, KJ ;
BRANDSBORG, M ;
BRANDSBORG, O .
ACTA ENDOCRINOLOGICA, 1979, 91 (03) :564-570
[8]   NORMAL CALCITONIN RESPONSE TO PENTAGASTRIN STIMULATION IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
ESCALADA, J ;
TERUEL, JL ;
PAVON, I ;
VILA, T ;
NAVARRO, J ;
VARELA, C .
ACTA ENDOCRINOLOGICA, 1993, 129 (01) :39-41
[9]  
GRAUER A, 1992, CANCER RES, V125, P55
[10]   DIAGNOSIS OF MEDULLARY CARCINOMA OF THE THYROID (MCT) BY CALCITONIN ASSAY USING MONOCLONAL-ANTIBODIES - CRITERIA FOR THE PENTAGASTRIN STIMULATION TEST IN HEREDITARY MCT [J].
GUILLOTEAU, D ;
PERDRISOT, R ;
CALMETTES, C ;
BAULIEU, JL ;
LECOMTE, P ;
KAPHAN, G ;
MILHAUD, G ;
BESNARD, JC ;
JALLET, P ;
BIGORGNE, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (04) :1064-1067